Sorrento Therapeutics Inc (SRNE)

[1776club]

Hummm...cashflow a commin.
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm Ltd (HK:2181) has received approval of its New Drug Application for its infliximab biobetter antibody in China.

Global sales revenue of infliximab in 2020 reached $4.2 billion, making the antibody one of the top 20 blockbuster drugs.

The new Infliximab biobetter antibody produced in CHO cells has demonstrated a better safety profile than the parent mouse cell produced product, while maintaining its efficacy profile.

Sorrento is planning to meet with FDA and EMA to discuss the data package and gain concurrence on the path forward to a BLA or MAA.

https://stockhouse.com/news/press-releases/2021/07/20/sorrento-announces-its-partner-mabpharm-has-received-marketing-approval-in-china